Status:
COMPLETED
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
Lead Sponsor:
Acorda Therapeutics
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 s...
Detailed Description
Multiple sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing com...
Eligibility Criteria
Inclusion
- Patient must have been previously enrolled in the Acorda Therapeutics MS-F204 study and received either Fampridine-SR or placebo
- Patient with clinically defined multiple sclerosis (the diagnostic criteria based on: McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001; 50: 121-127)
- Patient must be at least 18 years of age. Any patient who is now over the age of 70 must be in good overall health in the judgment of the investigator
- Patient must be of adequate cognitive function, as judged by the Investigator
- Patients who are women of childbearing potential must have a negative urine pregnancy test at the screening visit
Exclusion
- Female patients who are either pregnant or breastfeeding.
- Women of childbearing potential who are not using a specified birth control method
- Patients discontinued prematurely from the MS-F204 study
- Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG
- Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit
- Patient with severe renal impairment
- Patient with angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator
- Patient with a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet
- Patient who has received an investigational drug (other than Fampridine-SR or placebo under MS-F204 study) within 30 days of the MS-F204EXT screening visit or a patient who is scheduled to enroll in an investigational drug trial at any time during this study
- Patient who has a history of drug or alcohol abuse within the past year
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT00649792
Start Date
August 1 2007
End Date
April 1 2011
Last Update
February 28 2012
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
2
HOPE Research Institute
Phoenix, Arizona, United States, 85050
3
Neurological Associates
Fayetteville, Arkansas, United States, 72703
4
Alta Bates Summit Medical Center - Research and Education Institute
Berkeley, California, United States, 94705